Isodon Holding

Isodon Holding is a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics derived from natural products, specifically diterpenoids from the Isodon genus. The company's core technology centers on the chemical modification of oridonin, a bioactive compound extracted from the medicinal herb Isodon rubescens, to enhance its pharmacological properties and therapeutic index. Its lead clinical candidate, HA-1212, is a semi-synthetic oridonin derivative currently being evaluated in Phase 1/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML). Isodon Holding aims to address unmet needs in oncology and inflammatory diseases by targeting pathways such as the NLRP3 inflammasome and NF-kappaB. The company leverages deep expertise in natural product chemistry and maintains strong collaborative ties with academic research institutions in China. Through its specialized platform, Isodon Holding is working to translate traditional medicinal knowledge into modern, targeted therapies with improved safety and efficacy profiles.